Dive into the archives.
- Genzyme’s Alemtuzumab Granted Fast Track Status by FDA for RRMS
CAMBRIDGE, Mass., Jun 14, 2010 (BUSINESS WIRE) — Genzyme Corporation /quotes/comstock/15*!genz/quotes/nls/genz (GENZ 49.50, +0.45, +0.92%) announced today that its alemtuzumab for multiple sclerosis development program has been granted Fast Track status by the U.S. Food and Drug Administration (FDA). This designation covers patients with relapsing-remitting forms of the disease. View full post here: http://www.marketwatch.com/story/genzymes-alemtuzumab-for-treatment-of-multiple-sclerosis-granted-fast-track-status-by-fda-2010-06-14?reflink=MW_news_stmp
- Biogen Receives FDA Fast Track Status for PEGylated Interferon Beta-1a
July 8, 2009 Biogen Idec (NASDAQ: BIIB) today announced the U.S. Food and Drug Administration (FDA) has granted PEGylated interferon beta-1a (BIIB017) Fast Track designation for relapsing multiple sclerosis (RMS). Biogen Idec is currently enrolling patients in a global Phase III study evaluating the efficacy and safety of either bi-weekly or once-monthly injections of PEGylated [...]
- Hot off the AAN Press: Laquinimod, New Data, Novel MOA
New Data Illustrate Novel Mechanism OF Action of Laquinimod, an Oral Compound for the Treatment of Multiple Sclerosis -Researchers Demonstrate Immunomodulatory Effects of Laquinimod on Disease Activity Jerusalem, Israel, Lund, Sweden and Seattle, Washington, April 28, 2009 – Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) and Active Biotech (NASDAQ OMX NORDIC: ACTI) today announced results from [...]
- The Age of Orals: Who Will Win the Race to the Market?
Jan 23, 2009 Oral Cladribine Reduces MS Relapses in Phase 3 Clinical Trial Oral cladribine (EMD Serono) reduced the relapse rate significantly more than inactive placebo in the phase 3 “CLARITY” study of 1,326 people with relapsing-remitting MS. These initial results – the first from any phase 3 study of oral therapy for MS — [...]
